Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-31

Clinical Trial Update: The Efficacy and Safety of KN046 Combined With Axitinib [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on KN046 with axitinib for non-small cell lung cancer (NSCLC) across Phase 2 and Phase 3, with status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Axitinib (Axitinib)
  • KN046

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC | Phase 2, Phase 3 | Status: UNKNOWN